220 related articles for article (PubMed ID: 24591092)
1. Low-dose lamotrigine augmentation therapy improves residual symptoms in treatment-resistant schizophrenia: a report of five cases.
Ohnuma T; Takebayashi Y; Higashiyama R; Shibata N; Arai H
Asia Pac Psychiatry; 2013 Dec; 5(4):336-43. PubMed ID: 24591092
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
Goff DC; Keefe R; Citrome L; Davy K; Krystal JH; Large C; Thompson TR; Volavka J; Webster EL
J Clin Psychopharmacol; 2007 Dec; 27(6):582-9. PubMed ID: 18004124
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.
Kremer I; Vass A; Gorelik I; Bar G; Blanaru M; Javitt DC; Heresco-Levy U
Biol Psychiatry; 2004 Sep; 56(6):441-6. PubMed ID: 15364042
[TBL] [Abstract][Full Text] [Related]
4. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.
Glick ID; Bosch J; Casey DE
J Clin Psychopharmacol; 2009 Jun; 29(3):267-71. PubMed ID: 19440081
[TBL] [Abstract][Full Text] [Related]
5. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
Strzelecki D; Rabe-Jabłońska J
Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
[TBL] [Abstract][Full Text] [Related]
6. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study.
Zoccali R; Muscatello MR; Bruno A; Cambria R; Micò U; Spina E; Meduri M
Schizophr Res; 2007 Jul; 93(1-3):109-16. PubMed ID: 17383857
[TBL] [Abstract][Full Text] [Related]
7. Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity.
Williams HJ; Zamzow CR; Robertson H; Dursun SM
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):239-43. PubMed ID: 16303224
[TBL] [Abstract][Full Text] [Related]
8. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.
Dursun SM; Deakin JF
J Psychopharmacol; 2001 Dec; 15(4):297-301. PubMed ID: 11769825
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.
Tiihonen J; Wahlbeck K; Kiviniemi V
Schizophr Res; 2009 Apr; 109(1-3):10-4. PubMed ID: 19186030
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease.
Genton P; Gelisse P; Crespel A
Epilepsia; 2006 Dec; 47(12):2083-5. PubMed ID: 17201707
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive lamotrigine in treatment-resistant schizophrenia.
Thomas R; Howe V; Foister K; Keks N
Int J Neuropsychopharmacol; 2006 Feb; 9(1):125-7. PubMed ID: 16004622
[No Abstract] [Full Text] [Related]
12. The potential role of lamotrigine in schizophrenia.
Large CH; Webster EL; Goff DC
Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia.
Pavlovic ZM
J Clin Psychopharmacol; 2008 Feb; 28(1):119-20. PubMed ID: 18204363
[No Abstract] [Full Text] [Related]
14. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.
Uzun O
J Psychopharmacol; 2010 Mar; 24(3):425-7. PubMed ID: 19010977
[TBL] [Abstract][Full Text] [Related]
15. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of antipsychotics with electroconvulsive therapy in treatment-resistant schizophrenia patients with dominant negative symptoms: a pilot study of effectiveness.
Pawełczyk T; Kołodziej-Kowalska E; Pawełczyk A; Rabe-Jabłońska J
Neuropsychobiology; 2014; 70(3):158-64. PubMed ID: 25358377
[TBL] [Abstract][Full Text] [Related]
17. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms.
Poyurovsky M; Glick I; Koran LM
J Psychopharmacol; 2010 Jun; 24(6):861-6. PubMed ID: 19074541
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lamotrigine add-on therapy in severe partial epilepsy in adults with drop seizures and secondary bilateral synchrony on EEG.
Bisulli F; Baruzzi A; Rosati A; Riva R; Avoni P; Cerullo A; Tinuper P
Epileptic Disord; 2001 Sep; 3(3):151-6. PubMed ID: 11679308
[TBL] [Abstract][Full Text] [Related]
19. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
Strzelecki D; Kropiwnicki P; Rabe-Jabłońska J
Psychiatr Pol; 2013; 47(4):609-20. PubMed ID: 24946468
[TBL] [Abstract][Full Text] [Related]
20. Glutamatergic agents for schizophrenia: current evidence and perspectives.
Zink M; Correll CU
Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
